★ WIDE MOAT STOCKS & COMPETITIVE ADVANTAGES ★
VOL. XCIV, NO. 247
Gilead Sciences, Inc.
GILD · NASDAQ Global Select Market
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Request update
Spot something outdated? Send a quick note and source so we can refresh this profile.
Overview
Gilead is a biopharmaceutical company with Q1 2026 product sales concentrated in HIV (~72%), plus oncology, liver disease, Veklury and mature products. The HIV moat is Biktarvy’s de facto clinical-standard position plus time-bounded patent protection, including 2036 settlement timing for certain U.S. generic entrants; generic clinical competition factors did not prove separate patient switching costs. Oncology retains cell-therapy manufacturing know-how, but required treatment sites, REMS programs and an acquired pipeline filing were not separate moats. Liver disease retains patent protection. Veklury and Other have no durable moat under the available evidence. Key pressures are Medicare negotiation, patent cliffs, rebates, modality competition and oncology execution.
Primary segment
HIV
Market structure
Oligopoly
Market share
—
HHI: —
Coverage
5 segments · 8 tags
Updated 2026-07-12
Segments
HIV
HIV treatment and prevention medicines (antiretroviral therapy and PrEP)
Revenue
72.4%
Structure
Oligopoly
Pricing
moderate
Share
—
Peers
Oncology (Cell Therapy + Trodelvy)
Oncology therapeutics focused on CAR T-cell therapy and antibody-drug conjugates (ADC)
Revenue
11.6%
Structure
Oligopoly
Pricing
moderate
Share
—
Peers
Liver Disease
Liver disease therapeutics (viral hepatitis and cholestatic liver disease)
Revenue
11%
Structure
Oligopoly
Pricing
weak
Share
—
Peers
Veklury (Remdesivir)
Hospital antiviral therapies for COVID-19
Revenue
2.1%
Structure
Competitive
Pricing
weak
Share
—
Peers
Other Products
Other specialty and legacy therapeutics (e.g., antifungals, PAH, other mature products)
Revenue
2.8%
Structure
Competitive
Pricing
weak
Share
—
Peers
Moat Claims
HIV
HIV treatment and prevention medicines (antiretroviral therapy and PrEP)
Revenue_share computed from Q1 2026 product sales in the earnings release: HIV $5,032m / total product sales $6,946m. Current proxy supports HIV leadership but does not provide a numeric Biktarvy treatment market share, so the prior share estimate was removed.
De Facto Standard
Network
De Facto Standard
Strength
Durability
Confidence
Evidence
Biktarvy's position as the most-prescribed HIV treatment regimen makes it a de facto clinical standard, reinforced by broad use and payer access.
De Facto Standard moat: definition, examples, and stocks
Erosion risks
- Competitor long-acting regimens (e.g., injectable treatment/PrEP) gaining share
- Generic entry after patent expiry
- Payer/formulary actions increasing rebates or steering to alternatives
Leading indicators
- Biktarvy and overall HIV portfolio market share trends
- Net realized price and gross-to-net deductions
- Guideline placement and new-start share
Counterarguments
- High-performing alternatives (including long-acting options) can shift prescriber behavior
- Formulary restrictions can override prescriber preference
IP Choke Point
Legal
IP Choke Point
Strength
Durability
Confidence
Evidence
Patents and regulatory exclusivities (and related litigation/settlements) delay generic entry for major HIV products, though timing is finite and litigated.
IP Choke Point moat: definition, examples, and stocks
Erosion risks
- Adverse court rulings or settlements enabling earlier generic entry
- Patent expirations and loss of exclusivity cycles
- Regulatory actions affecting exclusivity or pricing
Leading indicators
- Key patent litigation milestones and outcomes
- Patent expiry timelines for core HIV products
- Generic or authorized-generic launches
Counterarguments
- Strong brands can still see rapid erosion when generics enter
- Competitors can innovate around patents with new mechanisms or delivery
Oncology (Cell Therapy + Trodelvy)
Oncology therapeutics focused on CAR T-cell therapy and antibody-drug conjugates (ADC)
Revenue_share computed from Q1 2026 product sales in the earnings release: Cell Therapy $407m plus Trodelvy $402m / total product sales $6,946m. Trodelvy grew 37% year over year, while cell therapy sales fell 12% from competitive headwinds.
Capex Knowhow Scale
Supply
Capex Knowhow Scale
Strength
Durability
Confidence
Evidence
Scaled cell therapy manufacturing know-how (speed, reliability) is a differentiator; faster turnaround can expand treatable patients and clinician preference.
Capex Knowhow Scale moat: definition, examples, and stocks
Erosion risks
- Manufacturing disruptions or capacity constraints
- Process improvements adopted by competitors
- Technology shifts to off-the-shelf or in-vivo approaches
Leading indicators
- Turnaround time and capacity expansion disclosures
- Regulatory inspection outcomes for manufacturing sites
- Adoption of next-generation products/indications
Counterarguments
- Turnaround time alone may not determine choice if efficacy/safety differs
- Next-gen therapies could reset learning curves and reduce incumbency advantages
Liver Disease
Liver disease therapeutics (viral hepatitis and cholestatic liver disease)
Revenue_share computed from Q1 2026 product sales in the earnings release: Liver Disease $767m / total product sales $6,946m. Q1 growth reflected higher Livdelzi demand offset by inventory dynamics and lower HCV sales.
IP Choke Point
Legal
IP Choke Point
Strength
Durability
Confidence
Evidence
Patents and settlement agreements around TAF support exclusivity defense for products including Vemlidy, but this protection is time-bounded.
IP Choke Point moat: definition, examples, and stocks
Erosion risks
- Loss of exclusivity for core components
- Generic/authorized-generic launches
- Competitor innovation in HBV/HDV/PBC
Leading indicators
- Key patent expiry and litigation milestones
- Net price trajectory for Vemlidy and other liver products
- Competitor trial readouts and approvals
Counterarguments
- IP has a finite timeline; erosion can be rapid post-LOE
- Novel competitors can leapfrog legacy mechanisms
Veklury (Remdesivir)
Hospital antiviral therapies for COVID-19
Revenue_share computed from Q1 2026 product sales in the earnings release: Veklury $144m / total product sales $6,946m. Veklury sales fell 52% year over year due to lower COVID-19 hospitalization rates. Six months of pediatric exclusivity is too short and fragile to assign a durable moat.
Insufficient segment-specific evidence to assign a moat claim.
Other Products
Other specialty and legacy therapeutics (e.g., antifungals, PAH, other mature products)
Revenue_share computed as residual Q1 2026 product sales: total product sales $6,946m less HIV, Oncology, Liver Disease and Veklury = $194m. A proprietary formulation description without evidence of protected exclusivity or durable preference was not treated as a brand moat.
Insufficient segment-specific evidence to assign a moat claim.
Evidence
Biktarvy is the most-prescribed HIV treatment regimen
Proxy statement describes Biktarvy as the most-prescribed HIV regimen with over one million users and notes Yeztugo reached about 90% U.S. payer coverage by year-end 2025.
Patents and other proprietary rights are very important
The 10-K emphasizes reliance on patents and proprietary rights to protect key products.
no generic entry by the parties
The 10-K discloses settlement agreements with generic manufacturers that delay U.S. Biktarvy generic entry for those parties until 2036, subject to acceleration provisions.
The 10-K highlights that quality, reliability and speed are critical in cell therapy manufacturing, underscoring the operational barrier.
The 10-K discusses agreements settling patent litigation to protect TAF across multiple products, including Vemlidy.
Risks & Indicators
Erosion risks
- Competitor long-acting regimens (e.g., injectable treatment/PrEP) gaining share
- Generic entry after patent expiry
- Payer/formulary actions increasing rebates or steering to alternatives
- Adverse court rulings or settlements enabling earlier generic entry
- Patent expirations and loss of exclusivity cycles
- Regulatory actions affecting exclusivity or pricing
Leading indicators
- Biktarvy and overall HIV portfolio market share trends
- Net realized price and gross-to-net deductions
- Guideline placement and new-start share
- Key patent litigation milestones and outcomes
- Patent expiry timelines for core HIV products
- Generic or authorized-generic launches
Research GILD elsewhere
Keep the research going
More Rankings & Systems
Quality Stocks
High quality stocks ranked by profitability, margins, free cash flow quality, durability, solvency, and accounting...
Stock rankingUndervalued Stocks
Undervalued stocks from the NA & Europe universe, ranked with a multi-measure value system and quality controls.
Stock rankingDividend Stocks
Dividend stocks ranked by payout yield, payout sustainability, dividend growth, quality, balance-sheet safety, risk...
Stock rankingDefensive Stocks
Defensive stocks ranked by low volatility, low beta, intermediate momentum, durable profitability, balance sheet...
Stock rankingMomentum Stocks
Momentum stocks ranked by total return momentum, relative momentum, trend confirmation, and risk-adjusted momentum...
Stock rankingConviction 10
A concentrated 10-stock strategy from the NA & Europe universe, ranked across quality, value, growth, momentum, and...
Curation & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.